Pelareorep

Oncolytic virus

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Featured evidence outside this drug's tracked markets:NCT01166542 · Carcinoma · Phase 3 · completed · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT01166542 · Oncolytics Biotech
2010-06 – 2014-05 · Carcinoma, Squamous Cell of the Head and Neck
What this study did
Phase 2 (15)
Advanced Metastatic Colorectal Cancer
Other / comorbidity
NCT04445844 · Mridula George, MD
2020-07-13 – 2025-06-30 · Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
What this study did
NCT03723915 · Northwestern University
2018-11-14 – 2021-04-24 · Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT01199263 · National Cancer Institute (NCI)
2010-12-06 – 2020-07-17 · Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT01708993 · Canadian Cancer Trials Group
2012-12-10 – 2018-09-26 · Non Small Cell Lung Cancer
What this study did
NCT01656538 · Canadian Cancer Trials Group
2013-02-20 – 2018-02-14 · Metastatic Breast Cancer
What this study did
NCT01619813 · Canadian Cancer Trials Group
2012-12-14 – 2016-05-20 · Prostate Cancer
What this study did
NCT00861627 · Oncolytics Biotech
2009-03 – 2015-11 · Carcinoma, Non-small Cell Lung
What this study did
NCT00998192 · Oncolytics Biotech
2009-10 – 2015-08 · Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
What this study did
NCT00998322 · Oncolytics Biotech
2009-10 – 2015-02 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT00984464 · Oncolytics Biotech
2009-09 – 2014-10 · Metastatic Melanoma
What this study did
NCT00753038 · Oncolytics Biotech
2008-08 – 2013-05 · Carcinoma, Squamous Cell of the Head and Neck
What this study did
NCT00503295 · Oncolytics Biotech
2007-06 – 2011-04 · Osteosarcoma, Ewing Sarcoma Family Tumors, Malignant Fibrous Histiocytoma, Sarcoma, Synovial, Fibrosarcoma, Leiomyosarcoma
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT07280377 · Oncolytics Biotech
2021-10-27 – 2028-12-31 · Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
What this study did
NCT05514990 · University of Southern California
2022-10-07 – 2027-08-22 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT03282188 · University of Leeds
2017-10 – 2018-07 · Melanoma, Cancer of Skin
What this study did
Phase 1 (9)
Advanced Metastatic Colorectal Cancer
NCT01274624 · Oncolytics Biotech
2010-12 – 2018-11 · KRAS Mutant Metastatic Colorectal Cancer
What this study did
Other / comorbidity
NCT02101944 · National Cancer Institute (NCI)
2014-12-09 – 2024-05-07 · Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05519059 · Adlai Nortye Biopharma Co., Ltd.
2021-10-11 – 2023-05-30 · Advanced or Metastatic Breast Cancer
What this study did
NCT03605719 · Emory University
2018-10-24 – 2022-10-10 · Recurrent Plasma Cell Myeloma
What this study did
NCT04102618 · Oncolytics Biotech
2019-03-29 – 2022-04-20 · Breast Cancer
What this study did
NCT03015922 · University of Leeds
2017-06-05 – 2021-10-01 · Multiple Myeloma
What this study did
NCT02620423 · Oncolytics Biotech
2015-12 – 2018-08 · Pancreatic Adenocarcinoma
What this study did
NCT02723838 · Oncolytics Biotech
2017-02-28 – 2018-02-28 · Muscle-invasive Transitional Cell Carcinoma of the Bladder
What this study did
NCT00528684 · Oncolytics Biotech
2006-07 – 2010-06 · Malignant Glioma
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pelareorep: this drugPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
RP3
Discontinued
Oncolytic virusTumor cells (oncolytic replication)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pelareorep to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT05514990 · CT.gov ↗
What to watch
2027 (2)
July 2027 (1)
Phase 1/2Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic …Active not recruiting
Est. primary completion 2027-07-30 · NCT07280377 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Advanced Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-08-30 · NCT07446322 · CT.gov ↗
What to watch

See the full readout calendar ↗